Should I buy or sell YS Biopharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for YS Biopharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" YS shares. View YS analyst ratings or view top-rated stocks .

What is YS Biopharma's stock price target for 2024?

1 Wall Street analysts have issued 1-year price targets for YS Biopharma's shares. Their YS share price targets range from $5.25 to $5.25. On average, they predict the company's stock price to reach $5.25 in the next year. This suggests a possible upside of 623.1% from the stock's current price. View analysts price targets for YS or view top-rated stocks among Wall Street analysts .

How have YS shares performed in 2024?

YS Biopharma's stock was trading at $0.5110 on January 1st, 2024. Since then, YS shares have increased by 42.1% and is now trading at $0.7260. View the best growth stocks for 2024 here .

Are investors shorting YS Biopharma?

YS Biopharma saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 96,900 shares, a drop of 17.0% from the March 15th total of 116,800 shares. Based on an average trading volume of 211,800 shares, the days-to-cover ratio is currently 0.5 days. Currently, 0.5% of the shares of the company are sold short. View YS Biopharma's Short Interest .

When is YS Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, April 19th 2024. View our YS earnings forecast .

How were YS Biopharma's earnings last quarter?

YS Biopharma Co., Ltd. (NASDAQ:YS) announced its earnings results on Monday, January, 22nd. The company reported ($0.16) earnings per share (EPS) for the quarter. The company had revenue of $13.64 million for the quarter.

How do I buy shares of YS Biopharma?

Shares of YS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:YS

YS Biopharma (YS) Stock Price, News & Analysis

→ Forget NVIDIA, buy this $2 AI stock now… (From Behind the Markets) (Ad)

Free YS Stock Alerts

$0.73

-0.13 (-15.16%)

(As of 04:38 PM ET)

Compare

Today's Range: $0.70
▼
$0.88
50-Day Range: $0.38
▼
$0.94
52-Week Range: $0.35
▼
$1.97

Volume: 417,780 shs
Average Volume: 204,058 shs
Market Capitalization: $67.51 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.25

Get YS Biopharma alerts:

YS Biopharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 623.1% Upside
$5.25 Price Target
Short Interest: Healthy
0.54% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.28
Based on 9 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.49) to ($0.30) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.03 out of 5 stars

Medical Sector

345th out of 918 stocks

Pharmaceutical Preparations Industry

149th out of 417 stocks

3.5

Analyst's Opinion

Consensus Rating
YS Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
YS Biopharma has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.54% of the float of YS Biopharma has been sold short.
Short Interest Ratio / Days to Cover
YS Biopharma has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in YS Biopharma has recently decreased by 17.04%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
YS Biopharma does not currently pay a dividend.
Dividend Growth
YS Biopharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for YS.

2.4

News and Social Media Coverage

News Sentiment
YS Biopharma has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for YS Biopharma this week, compared to 1 article on an average week.
Search Interest
2 people have searched for YS on MarketBeat in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, YS Biopharma insiders have not sold or bought any company stock.
Percentage Held by Institutions
52.64% of the stock of YS Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for YS Biopharma are expected to grow in the coming year, from ($0.49) to ($0.30) per share.
Price to Book Value per Share Ratio
YS Biopharma has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About YS Biopharma Stock (NASDAQ:YS)

YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.

YS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

YS Stock News Headlines

April 19, 2024 | finanznachrichten.de

YS Biopharma Co., Ltd.: YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024

April 19, 2024 | finanznachrichten.de

YS Biopharma Co., Ltd.: YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024

April 19, 2024 | Behind the Markets (Ad)

The #1 Opportunity of the decade?

It's no wonder the Department of Defense is heavily invested in this technology. And why The Pentagon is pouring $20 billion into it.

April 19, 2024 | markets.businessinsider.com

YS Stock Earnings: YS Biopharma Co Misses EPS, Beats Revenue for Q3 2024

April 19, 2024 | prnewswire.com

YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024

April 18, 2024 | finanznachrichten.de

YS Biopharma Co., Ltd.: YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine

April 18, 2024 | prnewswire.com

YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine

April 18, 2024 | americanbankingnews.com

YS Biopharma (YS) Set to Announce Quarterly Earnings on Friday

April 19, 2024 | Behind the Markets (Ad)

The #1 Opportunity of the decade?

It's no wonder the Department of Defense is heavily invested in this technology. And why The Pentagon is pouring $20 billion into it.

April 16, 2024 | finance.yahoo.com

YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024

April 13, 2024 | americanbankingnews.com

Short Interest in YS Biopharma Co., Ltd. (NASDAQ:YS) Decreases By 17.0%

April 9, 2024 | msn.com

Chinese Biotech YS Biopharma's Next-Gen Rabies Vaccine Non-Inferior To Approved Competitor

April 9, 2024 | finanznachrichten.de

YS Biopharma Co., Ltd.: YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine

April 9, 2024 | finance.yahoo.com

YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine

April 9, 2024 | prnewswire.com

YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine

April 3, 2024 | finance.yahoo.com

YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility

March 28, 2024 | msn.com

Technology and demographics affect hiring and pay strategies

March 5, 2024 | finanznachrichten.de

YS Biopharma Co., Ltd.: YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries

March 5, 2024 | finance.yahoo.com

YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries

February 22, 2024 | finance.yahoo.com

YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024

February 17, 2024 | finanznachrichten.de

YS Biopharma Co., Ltd.: YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting

February 17, 2024 | finance.yahoo.com

YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting

February 16, 2024 | prnewswire.com

YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting

February 16, 2024 | finance.yahoo.com

Shareholders Led by Yi Zhang Announce Successful Results of Removal of Directors and Election of New Directors of YS Biopharma Co., Ltd.

February 16, 2024 | prnewswire.com

Shareholders Led by Yi Zhang Announce Successful Results of Removal of Directors and Election of New Directors of YS Biopharma Co., Ltd.

February 14, 2024 | finance.yahoo.com

YS Biopharma Announces Appointment of New Directors

February 14, 2024 | finance.yahoo.com

YS Biopharma to Hold an Extraordinary General Meeting on February 22, 2024 pursuant to a Shareholder Requisition to Enhance Corporate Governance

See More Headlines

Receive YS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for YS Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 1/22/2024
Today: 4/19/2024
Next Earnings (Confirmed): 4/19/2024
Fiscal Year End: 3/31/2025

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:YS
CUSIP: N/A
CIK: 1946399
Web: www.ysbiopharm.com
Phone: 852-2155-7212
Fax: N/A
Employees: 754
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.25
High Stock Price Target: $5.25
Low Stock Price Target: $5.25
Potential Upside/Downside: +514.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.65
Current Ratio: 1.41
Quick Ratio: 1.09

Sales & Book Value

Annual Sales: $100 million
Price / Sales: 0.80
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.14 per share
Price / Book: 0.75

Miscellaneous

Outstanding Shares: 93,060,000
Free Float: N/A
Market Cap: $79.57 million
Optionable: Not Optionable
Beta: 0.53

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Gang Li (Age 42)
Head of Marketing & Sales
Dr. Yuan Liu Ph.D. (Age 37)
Head of Vaccine Research
Dr. Hui Shao Ph.D. (Age 56)
President, CEO & Executive Director
Ms. Chunyuan Wu CPA (Age 46)
Chief Financial Officer & Director
Dr. Zenaida Reynoso Mojares (Age 65)
Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

YS Stock Analysis - Frequently Asked Questions

Should I buy or sell YS Biopharma stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for YS Biopharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" YS shares.
View YS analyst ratings or view top-rated stocks.
What is YS Biopharma's stock price target for 2024?: 1 Wall Street analysts have issued 1-year price targets for YS Biopharma's shares. Their YS share price targets range from $5.25 to $5.25. On average, they predict the company's stock price to reach $5.25 in the next year. This suggests a possible upside of 623.1% from the stock's current price.
View analysts price targets for YS or view top-rated stocks among Wall Street analysts.
How have YS shares performed in 2024?: YS Biopharma's stock was trading at $0.5110 on January 1st, 2024. Since then, YS shares have increased by 42.1% and is now trading at $0.7260.
View the best growth stocks for 2024 here.
Are investors shorting YS Biopharma?: YS Biopharma saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 96,900 shares, a drop of 17.0% from the March 15th total of 116,800 shares. Based on an average trading volume of 211,800 shares, the days-to-cover ratio is currently 0.5 days. Currently, 0.5% of the shares of the company are sold short.
View YS Biopharma's Short Interest.

When is YS Biopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, April 19th 2024.
View our YS earnings forecast.
How were YS Biopharma's earnings last quarter?: YS Biopharma Co., Ltd. (NASDAQ:YS) announced its earnings results on Monday, January, 22nd. The company reported ($0.16) earnings per share (EPS) for the quarter. The company had revenue of $13.64 million for the quarter.
How do I buy shares of YS Biopharma?: Shares of YS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:YS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial